Skip to content

Study · Case report or series · n = 1 · 2024

2 results

The first report of leukocytoclastic vasculitis induced by once-weekly subcutaneous semaglutide.

Pinheiro MM, de Souza LG, Nunes GP, Martin IF, de Oliveira YU, Pinheiro FMM, Costa LN, Caprio M, Della-Morte D, Infante M

Current medical research and opinion2 Aug 2024Cited by 10 (Europe PMC)

PMID39072425 (opens in a new tab)DOI10.1080/03007995.2024.2386047 (opens in a new tab)PepBankPUB-39072425
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a 73-year-old man with type 2 diabetes, once-weekly subcutaneous semaglutide was reported to have induced skin-limited leukocytoclastic vasculitis.

    In plain wordsIn one 73-year-old man with type 2 diabetes, weekly injected semaglutide was reported to have caused a skin-limited blood vessel inflammation.

    Peptide
    Semaglutide
    Outcome
    IncreaseLeukocytoclastic vasculitis
    Study

    n = 1

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Herein, we describe the first case of skin-limited LCV induced by once-weekly subcutaneous semaglutide in a 73-year-old man with T2DM, who experienced the complete resolution of the skin lesions shortly after the discontinuation of semaglutide therapy.
  2. 02HumanCase report or seriesSafety outcome

    In a 73-year-old man with semaglutide-induced vasculitis, the skin lesions resolved completely shortly after semaglutide was stopped.

    In plain wordsIn one man, the skin lesions went away completely soon after semaglutide was stopped.

    Peptide
    Semaglutide
    Outcome
    DecreaseResolution of skin lesions after discontinuation
    Study

    n = 1

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Herein, we describe the first case of skin-limited LCV induced by once-weekly subcutaneous semaglutide in a 73-year-old man with T2DM, who experienced the complete resolution of the skin lesions shortly after the discontinuation of semaglutide therapy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.